University of Maryland School of Medicine

Department of Emergency Medicine

University of Maryland School of Medicine Department of Emergency Medicine

UMEM Educational Pearls

Category: Cardiology

Title: fondaparinux in ACS

Keywords: fondaparinux, anticoagulation, acute coronary syndromes (PubMed Search)

Posted: 9/2/2007 by Amal Mattu, MD (Updated: 4/24/2014)
Click here to contact Amal Mattu, MD

Fondaparinux is a selective factor Xa inhibitor. Benefits of fodaparinux vs. heparin when anticoagulants are used in ACS: 1. It is not associated with heparin induced thrombocytopenia. 2. Significant reduction in 30-day and 6-month mortality vs. enoxaparin. 3. Significant reduction in bleeding complications. 4. Safer in patients with renal insufficiency vs. enoxaparin. Unfractionated heparin should be continued while the patient goes for PCI.